Search

Your search keyword '"Resegotti, L."' showing total 409 results
Start Over Author "Resegotti, L."
409 results on '"Resegotti, L."'

1. Therapy of Acute Myelogenous Leukemia in Adults

Author

Petti, M. C., Broccia, G., Caronia, F., Di Raimondo, F., Fioritoni, G., Ladogana, S., Leone, G., Liso, V., Musso, M., Neri, A., Peta, A., Petti, N., Resegotti, L., Tabilio, A., Vegna, M. L., Mandelli, F., Büchner, T., editor, Schellong, G., editor, Hiddemann, W., editor, and Ritter, J., editor

Published
1990
Full Text
View/download PDF

4. Molecular Pathogenesis of B-Cell Chronic Lymphocytic Leukemia: Analysis of 13q14 Chromosomal Deletions

Author

Migliazza, A., primary, Cayanis, E., additional, Bosch-Albareda, F., additional, Komatsu, H., additional, Martinotti, S., additional, Toniato, E., additional, Kalachikov, S., additional, Bonaldo, M. F., additional, Jelenc, P., additional, Ye, X., additional, Rzhetsky, A., additional, Qu, X., additional, Chien, M., additional, Inghirami, G., additional, Gaidano, G., additional, Vitolo, U., additional, Saglio, G., additional, Resegotti, L., additional, Zhang, P., additional, Soares, M. B., additional, Russo, J., additional, Fischer, S. G., additional, Edelman, I. S., additional, Efstratiadis, A., additional, and Dalla-Favera, R., additional

Published
2000
Full Text
View/download PDF

5. Therapy of Acute Myelogenous Leukemia in Adults

Author

Petti, M. C., primary, Broccia, G., additional, Caronia, F., additional, Di Raimondo, F., additional, Fioritoni, G., additional, Ladogana, S., additional, Leone, G., additional, Liso, V., additional, Musso, M., additional, Neri, A., additional, Peta, A., additional, Petti, N., additional, Resegotti, L., additional, Tabilio, A., additional, Vegna, M. L., additional, and Mandelli, F., additional

Published
1990
Full Text
View/download PDF

10. Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: an analysis of the EORTC-GIMEMA AML 8A trial

Author

Keating, S., Suciu, S., Witte, T.J.M. de, Mandelli, F., Willemze, R., Resegotti, L., Broccia, G., Thaler, J., Labar, B., Damasio, E., Bizzi, B., Rotoli, B., Vekhoff, A., Muus, P., Petti, M.C., Dardenne, M., Solbu, G., Vegna, M.L., and Zittoun, R.

Subjects
clonal remission after intensive antileukemic therapy (Biomed-2 1995) [European evaluation of intensive antileukemic therapy for patients with myelodysplastic syndrome (MDS) CRIANT]
Abstract

Contains fulltext : 22795___.PDF (Publisher’s version ) (Open Access)

Published
1996

11. Will Molecular Biology Contribute to Refine Prognosis and to Select Treatment?

Author

Zaccaria, A, Martinelli, G, Buzzi, M, Farabegoli, P, Saglio, G, Guerrasio, A, Bernabei, P, Santini, V, Pellicci, P, Mencarelli, A, Coco, F, Diverio, D, Rambaldi, A, Santoro, A, Tura, S, Russo, D, Zuffa, E, Fanin, R, Patriarca, F, Fiacchini, M, Baccarani, M, Testoni, N, Zamagni, M, Montefusco, E, Alimena, G, Meloni, G, Mandelli, F, Damiani, D, Michieli, M, Criscuolo, D, Fowst, C, Holdener, E, Specchia, G, Liso, V, Morra, E, Bernasconi, C, Demilio, A, Battista, R, Ditucci, A, Broccia, G, Maiolino, I, Caronia, F, Luciano, L, Rotoli, B, Leoni, P, Danieli, G, Bodenizza, C, Carotenuto, M, Rotondo, S, Nosari, A, Decataldo, F, Montuoro, A, Delaurenzi, A, Camillo, S, Liberati, A, Grignani, F, Tabilio, A, Martelli, M, Barbui, T, Leoni, F, Ciolli, S, Ronca, F, Nobile, F, Paolino, F, Resegotti, L, Papineschi, F, Spremolla, G, Landolfi, R, Leone, G, Volpe, E, Mangoni, L, Rizzoli, V, Capucci, A, Izzi, T, Scapoli, G, Castoldi, G, Gentilini, I, Coser, P, Gallo, E, Pileri, A, Cantonetti, M, Papa, G, Dini, D, Morandi, S, Bianchini, E, Pinotti, G, Venco, A, Zagonel, V, Pinto, A, Capaldi, A, Giovannelli, E, Pizzuti, M, Ricciuti, F, Ambrosetti, A, Cajozzo, A, Lombardo, M, Torlontano, G, Delfini, C, Lucarelli, G, Girino, M, Ascari, E, Risso, M, Damasio, E, Martino, S, Pardini, S, Longinotti, M, Miraglia, E, Debiase, R, Nardelli, S, Galieni, P, Dispensa, E, Abbadessa, A, Bruzzese, L, Prossomariti, L, Cimino, R, Derosa, C, Gabbas, A, Francesco, S, Gallamini, A, Difrancesco, A, Quaglino, D, Musolino, C, Squadrito, G, Avanzini, P, Gobbi, F, Nuova, A, Emilia, R, Aglietta, M, Camaschella, C, Mazza, M, Guglielmo, P, Cacciola, E, and Monaco, M

Subjects
INTERFERON, CHRONIC MYELOID LEUKEMIA, Cancer Research, PROGNOSIS, biology, Settore MED/06 - Oncologia Medica, business.industry, MOLECULAR BIOLOGY, Breakpoint, Transcript analysis, Hematology, HindIII, Bioinformatics, Restriction site, Text mining, Oncology, Risk index, biology.protein, Medicine, In patient, business, Settore MED/15 - Malattie del Sangue, Southern blot
Abstract

The possible prognostic value of the position of the breakpoint within the M-BCR in patients with Phl+ CML is still being debated. We analyzed the DNA rearrangements and the transcript types of 244 patients and tried to correlate the data obtained with prognostic features, defined according to Sokal's risk index, and with chronic phase and/or survival duration. The exact location of the breakpoint, either 5' or 3' to the Hind III restriction site within the M-BCR was identified. Moreover, the exact M-BCR subregion was also identified. As a whole, 150 pts were rearranged in the 5' part and 94 in the 3' part of the M-BCR. No correlation was observed between the site of rearrangement on the one hand and the Sokal's prognostic index and survival, on the other. Transcript analysis was performed in 130 patients; 59 carried an a2b2 and 69 an a2b3 pattern. Two patients carried both transcripts. Of the patients rearranged in the 5' area, according to Southern blotting, 29.2% showed an a2b3 transcript. Therefore, R...

Published
1993

12. MACOP-B treatment in diffuse large-cell lymphoma: identification of prognostic groups in an Italian multicenter study

Author

Vitolo, U, Bertini, M, Brusamolino, E, Cavallero, Gb, Comotti, B, Gallo, Eugenio, Ghio, R, Levis, A, Luxi, G, Meneghini, V, Novero, D, Orsucci, L, Rota Scalabrini, D, Tarella, Corrado, Todeschini, G, Viero, P, Barbui, T, Bernasconi, C, Perona, Gianni, Pileri, Alessandro, and Resegotti, L.

Subjects
Adult, Male, Cancer Research, medicine.medical_specialty, Vincristine, Adolescent, Cyclophosphamide, Leucovorin, Bleomycin, Gastroenterology, chemistry.chemical_compound, Risk Factors, Prednisone, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Doxorubicin, Aged, business.industry, Middle Aged, Prognosis, medicine.disease, Survival Analysis, Surgery, Lymphoma, Methotrexate, Oncology, chemistry, Multivariate Analysis, Regression Analysis, Female, Lymphoma, Large B-Cell, Diffuse, business, Progressive disease, medicine.drug
Abstract

PURPOSE The prognosis of advanced-stage diffuse large-cell lymphoma (DLCL) has improved with the use of the third-generation regimens such as methotrexate with leucovorin, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin (MACOP-B). However, different results have been reported. Therefore, we started a cooperative study to confirm the efficacy of MACOP-B. An analysis of prognostic factors was also performed to identify poor-prognosis patients. PATIENTS AND METHODS Between June 1986 and March 1989, 180 patients with advanced-stage DLCL were treated with MACOP-B. MACOP-B was given according to the original scheme. Numerous clinical features possibly predictive for complete response (CR), disease-free survival (DFS), and survival were analyzed in univariate and multivariate analyses. RESULTS One hundred twenty-seven patients (71%) achieved a complete remission, 20 (11%) achieved a partial remission, 24 (13%) had unchanged or progressive disease, and nine (5%) died due to toxicity. With a median follow-up of 28 months, 71% of 127 CRs remain in first remission. Predicted 3-year survival for all 180 patients is 60%, and 3-year DFS for the 127 CRs is 67%. Overall toxicity was acceptable, with mucositis being the most frequent severe side effect. A multivariate regression analysis identified lactate dehydrogenase (LDH) level, bone marrow involvement, and tumor burden as independent risk factors for survival. These factors were also important for achievement of remission and DFS and allowed us to identify three distinct risk groups of patients with good, intermediate, and poor prognosis, with 3-year survival rates of 80%, 59%, and %29, respectively. CONCLUSIONS These results confirm the effectiveness of MACOP-B in advanced-stage DLCL at low or intermediate risk; however, high-risk patients are in urgent need of new therapeutic approaches. A better definition of prognostic features would allow a more reliable comparison of different treatment regimens, as well as an effective tailoring of therapy by prognostic groups.

Published
1992

13. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes

Author

Ferrini, PR, Grossi, A, Vannucchi, AM, Barosi, G, Guarnone, R, Piva, N, Musto, P, Balleari, E, Castoldi,G, Rigolin, GM, Rossi, PF, Fabbri, A, Leoni, F, Ghio, R, Maiolo, AT, Cortelezzi, A, Calori, R, Morra, E, Cairoli, R, Gabbas, A, Cicalo, F, Rizzoli, V, Caramatti, C, Bernasconi, C, Bonfichi, M, Ascari, E, Carotenuto, M, Resegotti, L, Degani, G, Perona, G, Nadali, G, Ferrini, P, Grossi, A, Vannucchi, A, Barosi, G, Guarnone, R, Piva, N, Musto, P, Balleari, E, Castoldi, G, Rigolin, G, Rossi, P, Fabbri, A, Leoni, F, Ghio, R, Maiolo, A, Cortelezzi, A, Calori, R, Morra, E, Cairoli, R, Gabbas, A, Cicalo, F, Rizzoli, V, Caramatti, C, Bernasconi, C, Bonfichi, M, Ascari, E, Carotenuto, M, Resegotti, L, Degani, G, Perona, G, and Nadali, G

Subjects
Transferrin receptor, Transfusion, Anaemia, Erythropoietin, Myelodysplastic syndrome
Abstract

To evaluate the effect of recombinant human erythropoietin (rHuEpo) on the haemoglobin level and transfusion requirement in low-risk myelodysplastic syndromes (MDS), 87 patients were enrolled in a randomized doubleblind placebo-controlled study. 44 patients were assigned to epoetin α (150 U/kg/d s.c. for 8 weeks) and 43 to placebo arms. MDS types were homogenous in both groups: refractory anaemia (RA) 47.7-48.8%, refractory anaemia with ringed sideroblasts (RAS) 20.5-25.6%, refractory anaemia with excess of blasts (RAEB) (blasts < 10%) 31.8-25.6%. 14/38 evaluable patients responded to epoetin α versus 4/37 to placebo (P=0.007). 50% of RA responded to epoetin α versus 5.9% to placebo (P = 0.0072), RAS 37.5% v 18.2% (P = 0.6) and RAEB 16.7% v 11.1% (P = 1.00). 60% of non-pretransfused patients responded to epoetin α (Hb 8.35 ± 0.73 to 10.07 ± 1.87 g/dl), whereas a slight decrease was observed in the placebo group (8.4 ± 0.66 to 8.19 ± 0.92 g/dl) (P = 0.0004). Percentage of transfused patients was similar in both arms. Basal erythropoietin (Epo) serum levels > 200 mU/l predicted for a non-response. At week 4 sTfR levels were increased > 50% in responders (P = 0.013), whereas an increase < 18% predicted for non-response (P = 0.006). Leucocyte and platelet counts were not influenced by epoetin α treatment. Adverse events occurred in 31.8% of the rHuEpo-treated versus 42.9% of the placebo-treated patients (P = 0.2), and seven patients did not complete the course. In conclusion, rHuEpo was effective in the treatment of low-risk MDS. RA subtype, no transfusions prior to rHuEpo therapy, and low basal Epo levels were associated with higher probability of response. Soluble transferrin receptor level at the fourth week was an early predictor of response.

Published
1998

15. The impact of anthracyclines on feasibility of subsequent autologous or allogeneic transplantation and induced marrow toxicity: interim results of the EORTC - GIMEMA AML-10 trial

Author

Witte, T.J.M. de, Suciu, S., Zittoun, R., Resegotti, L., Liso, V., Willemze, R., Belhabi, A., Amadori, S., Giustolisi, R., Labar, B., Fioritoni, G., Rossi Ferrini, P.R., Leone, G., Jehn, U., Keating, S., Fazi, P., Rodts, P., Solbu, G., and Mandelli, F.

Subjects
Haematology
Abstract

Item does not contain fulltext

Published
2001

16. Risk-assessment in diffuse large cell lymphoma at first relapse. A study by the Italian Intergroup for Lymphomas

Author

Guglielmi, C., Martelli, M., Federico, M., Zinzani, Pl, Vitolo, U., Bellesi, G., Santini, G., Tarella, Corrado, Zallio, F., Pregno, P., DI RENZO, N., and Resegotti, L.

Subjects
Adult, Aged, 80 and over, Male, Salvage Therapy, relapse, Antibiotics, Antineoplastic, lymphoma, Middle Aged, Risk Assessment, Survival Analysis, Cohort Studies, Italy, Recurrence, lymphoma, relapse, prognosis, adults, transplantation, Antineoplastic Combined Chemotherapy Protocols, adults, Humans, Female, Lymphoma, Large B-Cell, Diffuse, Prospective Studies, prognosis, Aged, transplantation
Abstract

Our aim was to identify risk factors in adults with diffuse large cell lymphoma at first relapse.We studied 474 patients observed at 45 centers in Italy. Median time from diagnosis to relapse was 395 days, median age at relapse was 55 years and median follow-up from relapse was 3.3 years. Salvage therapy consisted of polychemotherapy in 79% of patients, monochemotherapy and/or radiotherapy and/or surgery alone in 16%, and palliative therapy in 5%. Salvage treatment was intensified with high-dose chemotherapy + stem cell transplant in 20% of patients. OS and PFS were compared by sex, International Prognostic Index at diagnosis, histology, B/T phenotype, initial treatment, salvage therapy, and features at relapse: time from diagnosis, LDH, stage, performance status and bone marrow involvement. Cox models, adjusted for salvage therapy, were performed with factors related to overall survival (OS) and progression-free survival (PFS).Overall response (complete + partial) was 63%, OS at 3 years 35% and PFS at 3 years 26%. Relapse within 12 months from diagnosis, elevated serum lactic dehydrogenase (LDH), advanced stage and poor performance status were independent adverse factors for OS and PFS. The cumulative number of adverse factors is proposed as prognostic index for DLCL at first relapse since it identifies risk groups (p0.0001) and has been validated (p=0.01). Moreover, it predicts OS and PFS in the selected group of patients with a responsive relapse (p0.0001).Delay from initial diagnosis, LDH, stage and performance status at relapse should be balanced in comparative studies of salvage therapy of adults with DLCL. Patients with more than 2 adverse factors are one third of all cases and deserve more effective salvage treatments.

Published
2001

17. Intensive consolidation therapy compared with standard consolidation and maintenance therapy for adults with acute myeloid leukaemia aged between 46 and 60 years: final results of the randomized phase III study (AML 8B) of the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups.

Author

Hengeveld, M., Suciu, S., Karrasch, M., Specchia, G., Marie, J.P., Muus, P., Petti, M.C., Rotoli, B., Amadori, S., Fioritoni, G., Leoni, P., Morra, E., Thaler, J., Resegotti, L., Fazi, P., Vignetti, M., Mandelli, F., Zittoun, R., Witte, T.J. de, Hengeveld, M., Suciu, S., Karrasch, M., Specchia, G., Marie, J.P., Muus, P., Petti, M.C., Rotoli, B., Amadori, S., Fioritoni, G., Leoni, P., Morra, E., Thaler, J., Resegotti, L., Fazi, P., Vignetti, M., Mandelli, F., Zittoun, R., and Witte, T.J. de

Abstract

01 juni 2012, Item does not contain fulltext, The most effective post-remission treatment to maintain complete remission (CR) in adults aged between 46 and 60 years with acute myeloid leukaemia (AML) is uncertain. Previously untreated patients with AML in CR after induction chemotherapy with daunorubicin and cytarabine were randomized between two intensive courses of consolidation therapy containing high-dose cytarabine, combined with amsacrine or daunorubicin and a standard consolidation and maintenance therapy containing standard dose cytarabine and daunorubicin. One hundred fifty-eight CR patients were assigned to the intensive group and 157 patients to the standard group. After a median follow-up of 7.5 years, the 4-year survival rate was 32 % in the intensive group versus 34 % in the standard group (P = 0.29). In the intensive group, the 4-year relapse incidence was lower than in the standard group: 55 and 75 %, respectively (P = 0.0003), whereas treatment-related mortality incidence was higher: 22 versus 3 % (P < 0.0001). Two intensive consolidation courses containing high-dose cytarabine as post-remission treatment in patients with AML aged between 46 and 60 years old did not translate in better long-term outcome despite a 20 % lower relapse incidence. Better supportive care and prevention of treatment-related complications may improve the overall survival after intensified post-remission therapy in this age group.

Published
2012

18. Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi

Author

Federico M, Vitolo U, Pl, Zinzani, Chisesi T, Clò V, Bellesi G, Magagnoli M, Liberati M, Boccomini C, Niscola P, Pavone V, Cuneo A, Santini G, Brugiatelli M, Luca Baldini, Rigacci L, and Resegotti L

Subjects
Adult, Male, Risk, NON-HODGKINS-LYMPHOMA, BONE-MARROW TRANSPLANTATION, LOW-GRADE LYMPHOMA, SINGLE-AGENT CHEMOTHERAPY, HIGH-DOSE THERAPY, B-CELL LYMPHOMA, COMBINATION CHEMOTHERAPY, MULTIVARIATE-ANALYSIS, MALIGNANT-LYMPHOMAS, NATURAL-HISTORY, Fever, Sweating, Blood Sedimentation, Weight Loss, Biomarkers, Tumor, Humans, Lymphoma, Follicular, Serum Albumin, Aged, Neoplasm Staging, Retrospective Studies, L-Lactate Dehydrogenase, Middle Aged, Prognosis, Combined Modality Therapy, Neoplasm Proteins, Survival Rate, Italy, Multivariate Analysis, Female
Abstract

Patients (n-987) with a histologically confirmed diagnosis of follicular lymphoma were studied with the aim of developing a prognostic model specifically devised for this type of lymphoma. We collected information on age, sex, Ann Arbor stage, number of extranodal disease sites, bone marrow (BM) involvement, bulky disease, B symptom criteria (fever, night sweats, and weight loss), performance status (PS), serum lactate dehydrogenase (LDH) level, serum albumin level, hemoglobin level, and erythrocyte sedimentation rate (ESR). In the training sample of 429 patients with complete data, multivariate analysis showed that age, sex, number of extranodal sites, B symptoms, serum LDH level, and ESR were factors predictive for overall survival. Using these 6 variables, a prognostic model was devised to identify 3 groups at different risk. The 5- and 10-year survival rate was 90% and 65% for patients at low risk, respectively; 75% and 54% for patients at intermediate risk; and 38% and 11% for those at high risk (log-rank test, 86.62; P. 0001). The model was also predictive (P =.0001) in the validation sample of 265 patients with complete data only for the 6 variables used in the development of the model and even in the group of 210 patients from the validation sample uniformly treated with doxorubicin-containing regimens (P =.0001). The prognostic model appears to be very useful in identifying patients with follicular lymphoma at low, intermediate, or high risk.

Published
2000

19. The type of anthracycline administered during remission induction and consolidation therapy of AML has an impact on feasibility of subsequent autologous or allogeneic transplantation and induced marrow toxicity: preliminary results of the EORTC-Gimema AML-10 randomized trial

Author

De Witte, T, Suiciu, S, Zittoun, R, Resegotti, L, Liso, V, Willemze, R, Belhabri, A, Amadori, S, Guistolisi, R, Labar, B, Fioritoni, G, Rossi-Ferrini, G, Leone, G, Jehn, U, Keating, S, Fazi, P, Rodts, P, Solbu, G, and Mandelli, F.

Subjects
xx
Abstract

xx

Published
2000

20. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: A randomized, placebo- controlled, double-blind, multicenter trial

Author

Menichetti, F., Del Favero, A., Martino, P., Bucaneve, G., Micozzi, A., Girmenia, C., Barbabietola, G., Pagano, L., Leoni, P., Giorgina Specchia, Caiozzo, A., Raimondi, R., Mandelli, F., Cascavilla, N., Rigolin, G., Deliliers, G. L., Martino, B., Peta, A., Ricci P., Fanci, R., Plano, W., Sivera, P., Zagonel, V., Caramatti, C., Invernizzi, R., Buelli, M., Bernasconi, C., Carella, A., Damasio, E., Biasi, R., Chierichini, A., Galieni, P., Grasso, M., Jacopino, P., Morra, E., Porcellini, A., Resegotti, L., Ricciuti, F., Picardi, M., Ronconi, F., Cimino, R., Ferrandina, C., Gabbas, A., and Mettivier, V.

Subjects
Oral, Adult, Male, Microbiology (medical), medicine.medical_specialty, Antifungal Agents, Neutropenia, Adolescent, Itraconazole, Placebo, Aspergillosis, Double-Blind Method, Internal medicine, Multicenter trial, medicine, Administration, Oral, Aged, Female, Hematologic Neoplasms, Humans, Middle Aged, Mycoses, Patient Compliance, Infectious Diseases, Mycosis, Fungemia, business.industry, medicine.disease, Surgery, Chemoprophylaxis, Administration, business, medicine.drug
Abstract

To evaluate the efficacy and safety of itraconazole oral solution for preventing fungal infections, a randomized, placebo-controlled, double-blind, multicenter trial was conducted: 405 neutropenic patients with hematologic malignancies were randomly assigned to receive either itraconazole, 2.5 mg/kg every 12 hours (201 patients), or placebo (204 patients). Proven and suspected deep fungal infection occurred in 24% of itraconazole recipients and in 33% of placebo recipients, a difference of 9 percentage points (95% confidence interval [CI], 0.6% to 22.5%; P = .035). Fungemia due to Candida species was documented in 0.5% of itraconazole recipients and in 4% of placebo recipients, a difference of 3.5 percentage points (95% CI, 0.5% to 6%; P = .01). Deaths due to candidemia occurred in none of the itraconazole recipients compared with 4 placebo recipients, a difference of 2 percentage points (95% CI, 0.05% to 4%; P = .06). Aspergillus infection was documented in four itraconazole recipients (one death) and one placebo recipient (one death). Side effects causing drug interruption occurred in 18% of itraconazole recipients and 13% of placebo recipients. Itraconazole oral solution was well-tolerated and effectively prevented proven and suspected deep fungal infection as well as systemic infection and death due to Candida species.

Published
1999

21. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes

Author

Ferrini, P. R., Grossi, A., Vannucchi, A. M., Barosi, G., Guarnone, R., Piva, N., Musto, P., Balleari, E, Investigator, Castoldi, Gianluigi, Piva, N, Rigolin, Gian Matteo, Rossi, P. F., Grossi, A, Fabbri, A, Leoni, F, Ghio, R, Maiolo, A. T., Cortelezzi, A, Calori, R, Morra, E, Cairoli, R, Gabbas, A, Cicalo, F, Rizzoli, V, Caramatti, C, Bernasconi, C, Bonfichi, M, Ascari, E, Barosi, G, Guarnone, R, Carotenuto, M, Musto, P, Resegotti, L, Degani, G, Perona, G, and Nadali, G.

Subjects
Anaemia, Erythropoietin, Myelodysplastic syndromes, Transferrin receptor, Transfusion
Published
1998

22. The influence of HLA-matched sibling donor availability on treatment outcome for patients with AML: an analysis of the AML 8A study of the EORTC Leukaemia Cooperative Group and GIMEMA

Author

Keating, S., Witte, T.J.M. de, Suciu, S., Willemze, R., Hayat, M., Labar, B., Resegotti, L., Ferrini, P.R., Caronia, F., Dardenne, M., Solbu, G., Petti, M.C., Vegna, M.L., Mandelli, F., and Zittoun, R.

Subjects
Kwaliteitscontrole en analyse van prognostische factoren bij patienten behandeld voor acute leukemie door de EORTC Leukemie Groep, Quality control and prognosis factor analysis in acute leukemia trials of the EORTC Leukemia Cooperative Group
Abstract

Item does not contain fulltext

Published
1998

25. Idarubicin in patients with diffuse large cell lymphomas: a randomized trial comparing VACOP-B (A= Doxorubicin) vs VICOP-B (I=Idarubicin)

Author

Bertini, M., Freilone, R., Botto, B., Calvi, R., Gallamini, A., Gatti, A. M., Liberati, A. M., Meneghini, V., Orlandi, E., Orsucci, L., Pizzuti, M., Scalabrini, D. R., Salvi, F., Todeschini, G., umberto vitolo, and Resegotti, L.

Subjects
Adult, Male, Neutropenia, Adolescent, Gastrointestinal Diseases, Author Keywords:malignant lymphoma, chemotherapy, anthracyclines KeyWords Plus:NON-HODGKINS-LYMPHOMA, CHEMOTHERAPY, MULTICENTER, LEUKEMIA, MODEL, CHOP, Infections, Bleomycin, Antineoplastic Combined Chemotherapy Protocols, randomized trial, Humans, Life Tables, Cyclophosphamide, diffuse large cell lymphoma, Idarubicin, Aged, Etoposide, Remission Induction, Middle Aged, Survival Analysis, Treatment Outcome, Doxorubicin, Vincristine, Prednisone, Female, Lymphoma, Large B-Cell, Diffuse, Chemical and Drug Induced Liver Injury, Cardiomyopathies
Abstract

Idarubicin is an effective drug in acute leukemia but its use in non-Hodgkin lymphomas (NHLs) is not yet well established. We evaluated its efficacy in patients with diffuse large cell lymphoma (DLCL) by means of a randomized trial comparing two 12-week regimens (VACOP-B and VICOP-B) which differed only in the anthracycline drug used (doxorubicin vs idarubicin).From January 1992 to December 1994, 104 patients aged less than 65 years with de novo advanced stage DLCL were enrolled. Fifty-two patients were treated with VACOP-B (doxorubicin 50 mg/sqm) and 52 with VICOP-B (idarubicin initially 8 mg/sqm and thereafter 10 mg/sqm).Clinical characteristics of the two groups were not significantly different. One HBsAg+ patient died of hepatic necrosis in the VICOP-B arm, and severe (WHO grade2) toxicities occurred in 7 patients treated with VACOP-B and in 5 treated with VICOP-B; the only significant difference was for mucositis (p = 0.02). Complete remission (CR) was obtained in 79% of patients receiving VACOP-B and in 56% (idarubicin 8 mg/sqm) and 75% (idarubicin 10 mg/sqm) of those in the VICOP-B group (p = n.s.). Prognostic factors that negatively affected CR were advanced stage in VACOP, bone marrow infiltration in both schedules. At a median follow-up of two years, overall survival (67% VACOP and 61% VICOP) and disease-free survival (65% and 67%, respectively) were not significantly different.Idarubicin is slightly less toxic than doxorubicin; at a dose of 10 mg/sqm the former is easily tolerated and shows the same efficacy as doxorubicin in the treatment of DLCL.

Published
1997

26. Hairy cell leukemia

Author

Federico, Massimo, Frassoldati, A., Artusi, Tullio, Castoldi, G. L., Lauria, F., Pileri, S., Pizzolo, G., Resegotti, L., Semenzato, G., and Damasio, E. E.

Subjects
malattia linfoproliferativa, Hairy Cell Leukemia (HCL)
Published
1995

29. INTERFERON ALFA-2A AS COMPARED WITH CONVENTIONAL CHEMOTHERAPY FOR THE TREATMENT OF CHRONIC MYELOID LEUKEMIA

Author

Tura, S, Baccarani, M, Zuffa, E, Russo, D, Zaccaria, A, Fiacchini, M, Testoni, N, Zamagni, M, Martinelli, G, Damiani, D, Michieli, M, Fowst, C, Holdener, E, Specchia, G, Liso, V, Morra, E, Bernasconi, C, Alimena, G, Mandelli, F, Leoni, P, Danieli, G, Nosari, A, Decataldo, F, Majolino, I, Caronia, F, Liberati, A, Grignani, F, Tabilio, A, Martelli, M, Paolino, F, Resegotti, L, Ditucci, A, Broccia, G, Leoni, F, Ciolli, S, Luciano, L, Rotoli, B, Perricone, R, Cajozzo, A, Montuoro, A, Delaurenzi, A, Volpe, E, Demilio, A, Battista, R, Capucci, A, Izzi, T, Scapoli, G, Castoldi, G, Lombardo, M, Torlontano, G, Landolfi, R, Leone, G, Delfini, C, Sparaventi, G, Papineschi, F, Spremolla, G, Risso, M, Marmont, A, Dini, D, Diprisco, U, Mangoni, L, Rizzoli, V, Girino, M, Ascari, E, Bodenizza, C, Carotenuto, M, Difrancesco, A, Quaglino, D, Nardelli, S, Ciccone, F, Miraglia, E, Debiase, R, Gallo, E, Pileri, A, Rambaldi, A, Barbui, T, Morandi, S, Bianchini, E, Derosa, C, Cimino, R, Ronca, F, Nobile, F, Cantonetti, M, Papa, G, Gallamini, A, Buffa, F, Musolino, C, Squadrito, G, Capaldi, A, Giovannelli, E, Pinotti, G, Venco, A, Zagonel, V, Pinto, A, Gentilini, I, Coser, P, Guglielmo, P, Cacciola, E, Pizzuti, M, Ricciuti, F, Fanin, R, Criscuolo, D, and Montefusco, E

Subjects
Settore MED/06 - Oncologia Medica, CHRONIC MYELOGENOUS LEUKEMIA, BONE-MARROW TRANSPLANTATION, THERAPY, Settore MED/15 - Malattie del Sangue
Published
1994

30. Long term results of interferon treatment in hairy cell leukemia

Author

Capnist, G., Federico, Massimo, Chisesi, T., Resegotti, L., Lamparelli, T., Fabris, P., Rossi, G., Invernizzi, R., Guarnaccia, C., Leoni, P., Lauria, F., Pagnucco, G., Frassoldati, A., and Damasio, E.

Subjects
Hairy cell leukemia, interferon
Published
1994

31. Long term results of alpha interferon as initial therapy and splenectomy as consolidation therapy in patients with hairy cell leukemia. Final report from the Italian cooperative group for HCL

Author

Federico, Massimo, Frassoldati, A., Lamparelli, T., Foa, R., Brugiatelli, M., Annino, L., Baldini, L., Capnist, G., Chisesi, T., Dicelle, Pf, Invernizzi, R., Lauria, F., Truini, M., Resegotti, L., Silingardi, Vittorio, and Damasio, Ee

Subjects
hairy cell leukemia, alpha interferon, splenectomy, therapy
Published
1994

33. EVALUATING SURVIVAL AFTER ALLOGENEIC BONE-MARROW TRANSPLANT FOR CHRONIC MYELOID-LEUKEMIA IN CHRONIC PHASE - A COMPARISON OF TRANSPLANT VERSUS NO-TRANSPLANT IN A COHORT OF 258 PATIENTS 1ST SEEN IN ITALY BETWEEN 1984 AND 1986

Author

Tura, S, Fanin, R, Russo, D, Zuffa, F, Fiacchini, M, Baccarani, M, Testoni, N, Zamagni, D, Zaccaria, A, Damiani, D, Michieli, M, Alimena, G, Montefusco, E, Mandelli, F, Morra, E, Bernasconi, C, Guglielmi, P, Cacciola, E, Battista, R, Dini, E, Specchia, G, Liso, V, Majolino, I, Caronia, F, Leoni, P, Danieli, G, Nosari, A, Decataldo, F, Paolino, F, Resegotti, L, Comotti, B, Barbui, T, Scapoli, G, Castoldi, G, Prossomariti, L, Montuori, R, Riccardi, A, Ascari, E, Landolfi, R, Bizzi, B, Lombardo, M, Torlontano, G, Leoni, F, Ferrini, P, Sparaventi, G, Delfini, C, Papineschi, F, Spremolla, G, Broccia, G, Nardelli, S, Ciccone, F, Deriu, L, Miraglia, E, Debiase, R, Bodenizza, C, Carotenuto, M, Rotondo, S, Gentilini, I, Coser, P, Capucci, A, Izzi, T, Luciano, L, Rotoli, B, Iacopino, P, Nobile, F, Cantonetti, M, Papa, G, Pinotti, G, Sala, G, Foa, P, Maiolo, M, Avanzini, P, Gobbi, F, Dore, F, Pardini, S, Ambrosetti, A, Perona, G, Dini, D, Liberati, A, Martelli, M, Grignani, F, Montuoro, A, Delaurenzi, A, Gallo, E, Pileri, A, Gallamini, A, Buffa, F, Abbadessa, A, Bruzzese, L, Derosa, C, Cimino, R, Mangoni, L, Rizzoli, V, Pizzuti, M, Ricciuti, F, Galieni, P, Dispensa, E, Zagonel, V, Pinto, A, Musolino, C, Squadrito, G, Perricone, R, Cajozzo, A, Morandi, S, Bianchini, E, Miliani, A, Monaco, M, Difrancesco, A, Quaglino, D, Rosti, G, Marangolo, M, Pasini, F, Diperri, T, Aglietta, M, and Gavosto, F

Subjects
RISK, Settore MED/06 - Oncologia Medica, CHRONIC MYELOGENOUS LEUKEMIA, CHRONIC GRANULOCYTIC-LEUKEMIA, CHEMOTHERAPY, IRRADIATION, RELAPSE, Settore MED/15 - Malattie del Sangue
Published
1993

35. PROGNOSTIC FACTORS IN CHRONIC MYELOID-LEUKEMIA - RELATIONSHIP WITH INTERFERON AND BONE-MARROW TRANSPLANTATION

Author

Tura, S, Russo, D, Fanin, R, Zuffa, E, Patriarca, F, Fiacchini, M, Baccarani, M, Testoni, N, Zamagni, M, Zaccaria, A, Montefusco, E, Alimena, G, Meloni, G, Mandelli, F, Damiani, D, Michieli, M, Silvestri, F, Virgolini, L, Criscuolo, D, Fowst, C, Holdener, E, Specchia, G, Liso, V, Morra, E, Bernasconi, C, Demilio, A, Battista, R, Ditucci, A, Broccia, G, Majolino, I, Caronia, F, Luciano, L, Rotoli, B, Leoni, P, Bodenizza, C, Carotenuto, M, Rotondo, S, Nosari, A, Decataldo, F, Montuoro, A, Delaurenzi, A, Liberati, A, Tabilio, A, Martelli, M, Rambaldi, A, Barbui, T, Leoni, F, Ciolli, S, Ronca, F, Nobile, F, Paolino, F, Resegotti, L, Papineschi, F, Spremolla, G, Landolfi, R, Leone, G, Volpe, E, Mangoni, L, Rizzoli, V, Capucci, A, Izzi, T, Gentilini, I, Coser, P, Gallo, E, Pileri, A, Cantonetti, M, Papa, G, Dini, D, Diprisco, U, Morandi, S, Bianchini, E, Pinotti, G, Venco, A, Zagonel, V, Pinto, A, Capaldi, A, Giovannelli, E, Pizzuti, M, Ricciuti, F, Ambrosetti, A, Perona, G, Perricone, R, Cajozzo, A, Lombardo, M, Torlontano, G, Delfini, C, Lucarelli, G, Girino, M, and Ascari, E

Subjects
CHRONIC MYELOID LEUKEMIA, PROGNOSIS, INTERFERON Addresses, Settore MED/06 - Oncologia Medica, BONE MARROW TRANSPLANTATION, Settore MED/15 - Malattie del Sangue
Published
1993

36. KARYOTYPIC CONVERSION BY INTERFERON AS PREPARATIVE TREATMENT FOR AUTOLOGOUS BMT IN PH POSITIVE CML

Author

Gobbi, M, Tura, S, Russo, D, Zuffa, E, Patriarca, F, Fiacchini, M, Baccarani, M, Montefusco, E, Meloni, G, Mandelli, F, Zamagni, M, Testoni, N, Zaccaria, A, Fanin, R, Damiani, D, Michieli, M, Criscuolo, D, Fowst, C, Holdener, E, Specchia, G, Liso, V, Demilio, A, Battista, R, Ditucci, A, Broccia, G, Bodenizza, C, Carotenuto, M, Rotondo, G, Ambrosetti, A, Perona, G, Majolino, I, Caronia, F, Luciano, L, Rotoli, B, Morra, E, Bernasconi, C, Rambaldi, A, Barbui, T, Ronco, F, Nobile, F, Leoni, P, Nosari, A, Decataldo, F, Montuoro, A, Delaurenzi, A, Camillo, S, Gentilini, I, Coser, P, Dini, D, Diprisco, U, Papineschi, F, Spremolla, G, Liberati, A, Grignani, G, Tabilio, A, Martelli, M, Pardini, S, Longinotti, M, Mangoni, L, Rizzoli, V, Galieni, P, Dispensa, E, Abbadessa, A, Bruzzese, L, Leoni, F, Ciolli, S, Cantonetti, M, Papa, G, Landolfi, R, Leone, G, Gallo, E, Pileri, A, Zagonel, V, Pinto, A, Volpe, E, Difrancesco, A, Quaglino, D, Avanzini, P, Gobbi, F, Paolino, F, Resegotti, L, Saglio, G, Camaschella, C, Mazza, U, Pinotti, G, Venco, G, Capucci, A, Izzi, T, Morandi, S, Bianchini, E, Scapoli, G, Monaco, M, Pizzuti, M, Ricciuti, F, Capaldi, A, and Giovannelli, E

Subjects
INTERFERON, AUTOLOGOUS BMT, Settore MED/06 - Oncologia Medica, KARYOTYPIC CONVERSION, Settore MED/15 - Malattie del Sangue, PH+CML
Published
1993

37. TREATMENT OF PH-POSITIVE CHRONIC MYELOID-LEUKEMIA WITH ALPHA-INTERFERON (ROFERON-A) - THE ITALIAN COOPERATIVE STUDY-GROUP EXPERIENCE

Author

Tura, S, Russo, D, Zuffa, E, Fanin, R, Patriarca, F, Fiacchini, M, Baccarani, M, Testoni, N, Zamagni, M, Zaccaria, A, Montefusco, E, Alimena, G, Meloni, G, Mandelli, F, Damiani, D, Michieli, M, Criscuolo, D, Fowst, C, Holdener, E, Specchia, G, Liso, V, Morra, E, Bernasconi, C, Demilio, A, Battista, R, Ditucci, A, Broccia, G, Maiolino, I, Caronia, F, Luciano, L, Rotoli, B, Leoni, P, Danieli, G, Bodenizza, C, Carotenuto, M, Rotondo, S, Nosari, A, Decataldo, F, Montuoro, A, Delaurenzi, A, Camillo, S, Liberati, A, Grignani, F, Tabilio, A, Rambaldi, A, Barbui, T, Leoni, F, Ciolli, S, Ronca, F, Nobile, F, Paolino, F, Resegotti, L, Papineschi, F, Spremolla, G, Landolfi, R, Leone, G, Volpe, E, Mangoni, L, Rizzoli, V, Capucci, A, Izzi, T, Scapoli, G, Castoldi, G, Gentilini, I, Coser, P, Gallo, E, Pileri, A, Cantonetti, M, Papa, G, Dini, D, Diprisco, U, Morandi, S, Bianchini, E, Pinotti, G, Venco, A, Zagonel, V, Pinto, A, Capaldi, A, Giovannelli, E, Pizzuti, M, Ricciuti, F, Ambrosetti, A, Perona, G, Perricone, R, Cajozzo, A, Lombardo, M, Torlontano, G, Delfini, C, Lucarelli, G, Girino, M, Ascari, E, Risso, M, Damasio, E, Martino, S, Pardini, S, Longinotti, M, Miraglia, E, Debiase, R, Nardelli, S, Ciccone, F, Galieni, P, Dispensa, E, Abbadessa, A, Bruzzese, L, Prossomariti, L, Cimino, R, Derosa, C, Gabbas, A, Francesco, S, Gallamini, A, Difrancesco, A, Quaglino, D, Musolino, C, Squadrito, G, Avanzini, P, Gobbi, F, Nuova, A, Emilia, R, Saglio, G, Aglietta, M, Camaschella, C, Mazza, M, Guglielmo, P, Cacciola, E, and Monaco, M

Subjects
CHRONIC MYELOID LEUKEMIA, PHILADELPHIA CHROMOSOME, INTERFERON AUTOLOGOUS BONE MARROW TRANSPLANT, Settore MED/06 - Oncologia Medica, Settore MED/15 - Malattie del Sangue
Published
1993

39. Alpha-2b recombinant interferon (Intron) in Hodgkin's lymphoma: Therapeutic perspective

Author

Mazza, P., primary, Tura, S., additional, Bocchia, M., additional, Zinzani, P. L., additional, Gherlinzoni, F., additional, Mandelli, F., additional, Anselmo, M. P., additional, Papa, G., additional, Antimi, M., additional, Gobbi, P. G., additional, Porcellini, A., additional, Rizzoli, V., additional, Resegotti, L., additional, Levis, A., additional, Deriu, L., additional, Chierichini, A., additional, Ciccone, F., additional, Fanin, R., additional, Castoldi, G., additional, Scapoli, G. L., additional, Liso, V., additional, Chisesi, T., additional, Rancan, L., additional, and Amurri, B., additional

Published
2009
Full Text
View/download PDF

40. [Magnetic resonance in the study of residual mediastinal masses after therapy of lymphoma]

Author

ottavio davini, Levis A, Garabello D, Md, Foggetti, Depaoli L, Cirillo R, De Lucchi R, Orsucci L, and Resegotti L

Subjects
Predictive Value of Tests, Lymphoma, Non-Hodgkin, Humans, Neoplasm Recurrence, Local, Hodgkin Disease, Magnetic Resonance Imaging, Mediastinal Neoplasms, Sensitivity and Specificity, Follow-Up Studies
Abstract

Forty-five patients with mediastinal spread of malignant, Hodgkin's and non-Hodgkin's lymphomas were examined with MR Imaging at 0.5 T. Ninety-two examinations were performed at diagnosis and/or during and after treatment to investigate MR capabilities in distinguishing fibrous tissue from active disease in the masses residuing after therapy--which cannot be done by means of CT. MR results indicated T2-weighted sequences to be the most useful. MR results were compared with the data collected from follow-up, clinics, and biology. MR Imaging had high accuracy (92.1%). The number of false negatives was very low, thanks to the low intensity of fibrous tissue, while a relatively high number of false positives was observed, probably due to the difficulties in discriminating inflammatory from neoplastic tissue.

Published
1992

43. Different suppression of Ph1 positive hemopoiesis induced by intensive chemotherapy in lymphoid and myeloid blast crisis of CML

Author

Guerrasio, Angelo, Martinelli, G, Ambrosetti, A, Falda, M, Paolino, F, Regecambrin, G, Rosso, C, Pignatti, Pf, Gasparini, P, Perona, G, Resegotti, L, and Saglio, Giuseppe

Subjects
Gene Rearrangement, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Antineoplastic Combined Chemotherapy Protocols, Fusion Proteins, bcr-abl, Neoplastic Stem Cells, Humans, Blast Crisis, Polymerase Chain Reaction, Clone Cells, Hematopoiesis
Abstract

The suppression of Ph1-positive hemopoiesis is a major goal in the treatment of CML; in this context the CML patients in blast crisis obtaining a complete clinical remission represent a useful model to investigate the behavior of the Ph1-positive and negative clones during bone marrow repopulation after ablative therapy.Seven CML patients in blast crisis (four lymphoid and three myeloid) who obtained a complete clinical remission after an intensive polychemotherapy treatment were evaluated by cytogenetic and molecular analysis both in blast and remission phases. Standard cytogenetic and Southern techniques were employed; in addition, minimal residual disease status (MRD) was ascertained by amplification (PCR) of the specific bcr-abl chimeric transcripts.After a single cycle of induction, all lymphoid cases displayed a complete restoration of Ph1-negative hemopoiesis; by contrast, one myeloid blast crisis showed a partial suppression of Ph1-positive hemopoiesis only after two cycles of chemotherapy, and in the remaining two cases the hematological remission was indeed a reversion to the chronic phase.Ph1-positive chronic clones present in lymphoid blast crisis showed a higher degree of sensitivity to intensive chemotherapy than those present in the myeloid cases. This observation further suggests that the growth properties of the Ph1-positive clones are highly variable from case to case and probably tend to progress during the time-course of the disease.

Published
1991

44. Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients

Author

Boccadoro, M., Marmont, F., Tribalto, M., Awisati, G., Andriani, A., Barbui, T., Maria CANTONETTI, Carotenuto, M., Comotti, B., Dammacco, F., Frieri, R., Gallamini, A., Gallone, G., Giovangrossi, P., Grignani, F., Lauta, V. M., Liberati, M., Musto, P., Neretto, G., Petrucci, M. T., Resegotti, L., Pilerl, A., and Mandelli, F.

Subjects
Melphalan, Male, Cancer Research, Settore MED/06 - Oncologia Medica, vincristine EMTREE medical terms: article, THERAPY, Middle Age, priority journal MeSH:Aged, Prednisone, Antineoplastic Combined Chemotherapy Protocols, Non-U.S. Gov't, combination chemotherapy, Combination chemotherapy, Middle Aged, Prognosis, intravenous drug administration, Oncology, Vincristine, SURVIVAL, Female, Support, Multiple Myeloma, medicine.drug, medicine.medical_specialty, Cyclophosphamide, Urology, Drug Administration Schedule, medicine, Humans, Comparative Study, human, KINETICS, Aged, Carmustine, VINCRISTINE, business.industry, Induction chemotherapy, EMTREE drug terms:beta 2 microglobulin, major clinical study, Surgery, carmustine, cyclophosphamide, doxorubicin, melphalan, prednisone, female, male, multiple myeloma, beta 2-Microglobulin, Doxorubicin, Human, Support, Non-U.S. Gov't, Regimen, business, Settore MED/15 - Malattie del Sangue
Abstract

The efficacy of alternating vincristine, melphalan (M), cyclophosphamide, prednisone/vincristine, carmustine, doxorubicin, and prednisone (VMCP/VBAP) polychemotherapy was compared with the M and prednisone (MP) regimen as induction treatment in multiple myeloma (MM). Three hundred four MM patients entered this study between March 1983 and July 1986; the analysis was performed in December 1989. The treatment groups did not show significant differences with respect to major prognostic factors. Median overall survival was 33.8 months. In the VMCP/VBAP and MP arms, after 12 induction chemotherapy cycles, 59.0% and 47.3% (P less than .068) of the patients achieved an M component reduction greater than 50%. No significant difference was observed in the two treatment arms in terms of remission duration (21.3 v 19.6 months, P less than .66) and survival (31.6 v 37.0 months, P less than .28). Patients younger than 65 years did not show any advantage from the alternating polychemotherapy. At diagnosis, the plasma cell labeling index (LI) and serum beta-2 microglobulin (beta 2-m) were evaluated in 173 and 183 patients, respectively. A significantly reduced survival was observed for patients with LI greater than or equal to 2% (16.4 months) or beta 2-m greater than or equal to 6 mg/L (20.4 months). Even in these poor-risk subgroups, VMCP/VBAP was not superior to MP.

Published
1991

47. CONFIRMATION AND IMPROVEMENT OF SOKAL PROGNOSTIC CLASSIFICATION OF PH+ CHRONIC MYELOID-LEUKEMIA - THE VALUE OF EARLY EVALUATION OF THE COURSE OF THE DISEASE

Author

Tura, S, Russo, D, Zuffa, E, Fiacchini, M, Baccarani, M, Testoni, N, Zamagni, D, Zaccaria, A, Fanin, R, Damiani, D, Michieli, M, Alimena, G, Montefusco, E, Mandelli, F, Morra, E, Bernasconi, C, Guglielmi, P, Cacciola, E, Battista, R, Dini, E, Specchia, G, Liso, V, Majolino, I, Caronia, F, Leoni, P, Danieli, G, Nosari, A, Decataldo, F, Paolino, F, Resegotti, L, Comotti, B, Barbui, T, Scapoli, G, Castoldi, G, Prossomariti, L, Montuori, R, Riccardi, A, Ascari, E, Landolfi, R, Bizzi, B, Lombardo, M, Torlontano, G, Leoni, F, Ferrini, P, Sparaventi, G, Lucarelli, G, Papineschi, F, Spremolla, G, Broccia, G, Nardelli, S, Ciccone, F, Deriu, L, Miraglia, E, Debiase, R, Bodenizza, C, Carotenuto, M, Rotondo, S, Gentilini, I, Coser, P, Capucci, A, Izzi, T, Luciano, L, Rotoli, B, Iacopino, P, Nobile, F, Cantonetti, M, Papa, G, Pinotti, G, Sala, G, Foa, P, Maiolo, M, Avanzini, P, Gobbi, F, Dore, F, Longinotti, M, Ambrosetti, A, Perona, G, Dini, D, Diprisco, U, Liberati, A, Martelli, M, Grignani, F, Montuoro, A, Delaurenzi, A, Gallo, E, Pileri, A, Gallamini, A, Buffa, F, Abbadessa, A, Bruzzese, L, Derosa, C, Cimino, R, Mangoni, L, Rizzoli, V, Pizzuti, M, Ricciuti, F, Galieni, P, Dispensa, E, Zagonel, V, Pinto, A, Musolino, C, Squadrito, G, Perricone, R, Cajozzo, A, Morandi, S, Bianchini, E, Miliani, A, Monaco, M, Difrancesco, A, Quaglino, D, Rosti, G, Marangolo, M, Pasini, F, Diperri, T, Aglietta, M, and Gavosto, F

Subjects
MARROW TRANSPLANTATION, CHRONIC MYELOCYTIC-LEUKEMIA, Settore MED/06 - Oncologia Medica, CHRONIC MYELOGENOUS LEUKEMIA, DURATION, SURVIVAL, CHRONIC PHASE, CHRONIC GRANULOCYTIC-LEUKEMIA, MULTIVARIATE-ANALYSIS, BCR BREAKPOINT, DIAGNOSIS, Settore MED/15 - Malattie del Sangue
Published
1991

48. 'Different suppression of the Ph positive haemopoiesis induced by intensive chemotherapy in lymphoid and myeloid blast crisis of CML'

Author

Guerrasio, A., Martinelli, G., Ambrosetti, A., Falda, M., Paolino, F., REGE CAMBRIN, G., Rosso, C., Pignatti, P. F., Gasparini, Paolo, Perona, G., Resegotti, L., Saglio, G., A., Guerrasio, G., Martinelli, A., Ambrosetti, M., Falda, F., Paolino, G., REGE CAMBRIN, C., Rosso, Pignatti, P. F., Gasparini, Paolo, G., Perona, L., Resegotti, and G., Saglio

Published
1991

49. RECOMBINANT GAMMA-INTERFERON AS 1ST LINE THERAPY FOR HIGH-RISK MYELODYSPLASTIC SYNDROMES

Author

Maiolo, A. T., Cortelezzi, A., Calori, R., Polli, E. E., Gavosto, F., Piacibello, W., Resegotti, L., Paolino, R., Ascari, E., Cazzola, M., Bernasconi, C., Alessandrino, E. P., Castoldi, G. L., Mandelli, F., Alimena, Giuliana, ALOE SPIRITI, Maria Antonietta, and Cesana, B. M.

Subjects
granulocyte-macrophage, 13-cis retinoic acid, acute myelogenous leukemia, colony-stimulating factor, 13-cis-retinoic acid, acute myeloid-leukemia, dose cytosine-arabinoside, progenitor cells, prognostic factors, scoring system
Published
1990

Catalog

Books, media, physical & digital resources
See catalog results